Evidence map›Paper›PMID 38193760›Full record

ArticleInvestigative ophthalmology & visual science2024

Sjögren's Versus Non-Sjögren's Ocular Features: Similar Symptoms, But Significantly Worse Signs.

Fanxiu Xiong, Douglas Pula, Esen K Akpek, Vatinee Y Bunya, Caroline H Shiboski, Thomas L Lietman, John A Gonzales

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Fanxiu XiongFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States.
Douglas PulaFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States.
Esen K AkpekWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States.
Vatinee Y BunyaScheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Caroline H ShiboskiDepartment of Oral Medicine, University of California, San Francisco, San Francisco, California, United States.
Thomas L LietmanFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States.
John A GonzalesFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States.
University of California, San Francisco · USJohns Hopkins University · USPenn Presbyterian Medical Center · US

Funding

Sjögren's International Collaborative Clinical Alliance Next Generation Studies (SICCA-NextGen)U01DE028891 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHIBOSKI, CAROLINE HELENE · 2020 to 2024
$4.0M
Non-Sjogren's Syndrome-and Sjogren's Syndrome-related Keratoconjunctivitis SICCA: A Spectrum of Inflammatory Dry EyeK23EY026998 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GONZALES, JOHN ALEXANDER · 2016 to 2020
$1.3M
NEI NIH HHS K23 EY026998NHLBI NIH HHS HHSN268201300057CNIDCR NIH HHS U01 DE028891
6 · The paper itself

Abstract

Purpose: To examine the ocular signs and symptoms in participants of the Sjögren's International Collaborative Clinical Alliance cohort, and to compare them across Sjögren's disease (SjD) status. Methods: Our study population comprised 3380 Sjögren's International Collaborative Clinical Alliance participants who had no missing data relevant to this study. Participants' SjD status was assessed using the updated 2016 American College of Rheumatism/European League Against Rheumatism SjD classification criteria. Participants completed baseline questionnaires of ocular symptoms and underwent ocular examinations. Differences in the ocular signs and symptoms between SjD and non-SjD groups were assessed. We used multivariable linear and linear mixed-effects models to investigate the impact of SjD on Ocular Surface Disease Index-6 and OSS. Results: Among 1532 participants classified as SjD, their Ocular Surface Disease Index-6 did not clinically differ from those classified as non-SjD (adjusted difference, -0.97; 95% confidence interval, -1.52 to -0.41). However, SjD participants exhibited an elevated ocular staining score (adjusted difference, 3.47; 95% confidence interval, 3.36-3.57; P < 0.001) compared with non-SjD participants. In addition, SjD was associated with increased odds of ocular signs, such as reduced tear break-up time, abnormal Schirmer I test, and corneal abnormalities, and was strongly related to more intense corneal and conjunctival staining, as well as additional corneal staining points. Conclusions: SjD is associated with a higher risk of ocular signs and pathology compared with non-SjD, whereas ocular symptoms remain similar. In addition, corneal abnormalities and corneal staining patterns could serve as a potential biomarker in identifying SjD-related dry eye.

Indexed as

Rheumatic DiseasesSjogren's SyndromeConjunctivaCorneaHumansLinear Models

Identifiers

PMID38193760
PMCPMC10784845
OpenAlexW4390706481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.